NCT00883558View on ClinicalTrials.gov

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

April 30, 2010

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Insulin Lispro

DRUG

regular human insulin

DRUG

recombinant human hyaluronidase PH20

DRUG

Insulin glargine

Trial Locations (8)

27713

UNC Diabetes Care Center/Highgate Specialty Center, Durham

33136

Diabetes Research Institute, Miami

44195

Cleveland Clinic, Cleveland

48202

Henry Ford Health System, Detroit

59701

Mercury Street Medical, Butte

78731

Texas Diabetes and Endocrinology, Austin

80045

Barbara Davis Center for Childhood Diabetes, Aurora

98502

West Olympia Internal Medicine, Olympia

Sponsors
All Listed Sponsors
lead

Halozyme Therapeutics

INDUSTRY

NCT00883558 - Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter